ID
28373
Description
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment). Sponsor / Information provided by (Responsible Party): Boehringer Ingelheim. https://clinicaltrials.gov/ct2/show/NCT02239120?term=NCT02239120&cond=NCT02239120&rank=1
Lien
https://clinicaltrials.gov/ct2/show/NCT02239120?term=NCT02239120&cond=NCT02239120&rank=1
Mots-clés
Versions (1)
- 08/01/2018 08/01/2018 -
Détendeur de droits
Boehringer Ingelheim
Téléchargé le
8 janvier 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility criteria RE-SPECT ESUS Embolic Stroke NCT02239120
Eligibility criteria RE-SPECT ESUS Embolic Stroke NCT02239120
- StudyEvent: ODM
Description
Exclusion criteria
Description
Modified Rankin Scale
Type de données
boolean
Description
such as: a) intracardiac thrombus as evidenced by transthoracic or transesophageal echocardiography, b) paroxysmal, persistent or permanent AF, c) atrial flutter, d) prosthetic cardiac valve (mitral or aortic, bioprosthetic or mechanical), e) atrial myxoma, f) other cardiac tumors, g) moderate or severe mitral stenosis, h) recent (< 4weeks) myocardial infarction, i) valvular vegetations, or j) infective endocarditis
Type de données
boolean
Description
anticoagulant
Type de données
boolean
Description
History of atrial fibrillation
Type de données
boolean
Description
i.e. cerebral arteritis or arterial dissection, migraine with aura/vasospasm, drug abuse
Type de données
boolean
Description
Renal impairment with estimated creatinine clearance (as calculated by Cockcroft-Gault equation) <30mL/min at screening, or where Investigator expects creatinine clearance is likely to drop below 30mL/min during the course of the study
Type de données
boolean
Similar models
Eligibility criteria RE-SPECT ESUS Embolic Stroke NCT02239120
- StudyEvent: ODM